Artivion has presented new clinical data from two trials, one demonstrating better patient outcomes when using its On-X aortic valve, and another validating the safety of its AMDS hybrid prosthesis ...
Artivion has secured a green light from the FDA for its stentlike implant designed to help remodel the interior of the aortic arch following rare and severe tears within the lining of the major blood ...
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion Data from the trial demonstrate sustained benefit ...
ATLANTA - Artivion, Inc. (NYSE:AORT), a $1.93 billion market cap medical device company whose shares have surged 31.86% over the past six months, announced new clinical data from two trials evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results